NDAINTRAMUSCULARSOLUTION
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
SEIZALAM (midazolam hydrochloride) by Medcaptain Medical Technology is short-acting benzodiazepine central nervous system (cns) depressant. First approved in 2018.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEIZALAM is a short-acting benzodiazepine CNS depressant administered intramuscularly as a solution. Midazolam hydrochloride works by enhancing GABA-mediated inhibition in the central nervous system. The product is indicated for acute seizure management and related CNS emergencies.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable but not expanding team dynamics.
Mechanism of Action
short-acting benzodiazepine central nervous system (CNS) depressant.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
Started Apr 2018
3 enrolled
Nervous System Diseases
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
Started Oct 2017
25 enrolled
Nervous System Diseases
Career Relevance
SEIZALAM currently shows zero linked job postings, indicating stable team staffing at peak lifecycle stage. Career opportunities will emerge primarily in commercial defense and market maintenance roles rather than growth expansion.
Brand Manager
Worked on SEIZALAM at Medcaptain Medical Technology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.